

Date: 11th February, 2023
The Manager
BSE Ltd.
25th Floor, Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400 001
Script Code: 540359

Sub.: Outcome of the meeting of the Board of Directors of the Company

Dear Sirs,

In continuation of our Corporate announcement dated 4th February, 2023 we hereby inform you that the Board of Directors of the Company has, at its meeting held today, inter—alia, considered and approved the Unaudited Financial Results for quarter and nine months ended 31st December, 2022. The same has also been reviewed by the Audit Committee in its meeting held today. A copy of the Statement of Unaudited Financial Results for the quarter and Nine months ended 31st December, 2022 is enclosed.

Further we are submitting the Limited Review report on Unaudited Financial Results for quarter and Nine months ended 31st December, 2022 issued by our Statutory Auditors i.e. M/s. B A Shah S R Mehta & Co.

The meeting was commenced at 12.30 pm and was concluded at 2:00 pm.

Kindly take this on your records.

Thanking you,

Yours faithfully,

For, Parmax Pharma Limited

YASH
JAYESHBHAI
VORA

Digitally signed by YASH
JAYESHBHAI VORA
Date: 2023.02.11 14:20:21
+05'30'

Yash Vora
Company Secretary

Encl: As above

| Statement of Standalone Unaudited Results for the Quarter & Nine Months ended 31.12.2022 | | | | | | | |
|--|---|-----------------|-----------------|-----------------|-------------------|------------------|--------------------|
| | | | | | | | (in Rs. Thousands) |
| Sr. No. | Particulars | Quarter Ended | | | Nine Months Ended | | Year Ended |
| | | 31.12.2022 | 30.09.2022 | 31.12.2021 | 31.12.2022 | 31.12.2021 | 31.03.2022 |
| (Refer Notes Below) | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| I. | Revenue from operations | 53532.39 | 21338.18 | 28858.79 | 90424.12 | 111631.42 | 182511.20 |
| II. | Other income | 86.85 | 77.21 | 55.72 | 248.06 | 459.81 | 627.81 |
| III. | Total Income (I+II) | 53619.24 | 21415.39 | 28914.50 | 90672.18 | 112091.23 | 183139.00 |
| IV. | Expenses | | | | | | |
| | (a) Cost of materials consumed | 46908.44 | 4923.70 | 7737.21 | 64634.05 | 29526.69 | 67179.40 |
| | (b) Purchase of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | -41093.29 | 3405.12 | -1752.92 | -45683.80 | 32.63 | -61.00 |
| | (d) Employee benefits expense | 11403.82 | 5121.32 | 9633.78 | 22006.20 | 29774.68 | 34616.07 |
| | (e) Finance Costs | 1062.89 | 1170.99 | 1075.59 | 3147.93 | 3003.23 | 3858.12 |
| | (f) Depreciation and amortisation expense | 4776.35 | 4666.53 | 4849.48 | 14056.96 | 14327.09 | 19320.89 |
| | (g) Other expenses* | 13124.62 | 9153.53 | 12551.98 | 35281.12 | 33552.12 | 55192.82 |
| | Total expenses (IV) | 36182.83 | 28441.19 | 34095.12 | 93442.47 | 110216.44 | 180106.31 |
| V. | Profit/(Loss) from operations before exceptional items and tax (I-IV) | 17436.41 | -7025.81 | -5180.62 | -2770.29 | 1874.78 | 3032.70 |
| VI. | Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0 |
| VII. | Profit/ (Loss) before tax (V-VI) | 17436.41 | -7025.81 | -5180.62 | -2770.29 | 1874.78 | 3032.70 |
| VIII. | Tax expense: | | | | | | |
| | (1) Current tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2250.00 |
| | (2) Deferred tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 632.43 |
| IX. | Net Profit / (Loss) for the period from continuing operations (VII-VIII) | 17436.41 | -7025.81 | -5180.62 | -2770.29 | 1874.78 | 1415.13 |
| X. | Profit/(loss) from discontinued operations | | | | 0.00 | 0.00 | |
| XI. | Tax expense of discontinued operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0 |
| XII. | Profit/(loss) from Discontinued operations (after tax) (X-XI) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0 |
| XIII. | Profit (Loss) for the period (IX+XII) | 17436.41 | -7025.81 | -5180.62 | -2770.29 | 1874.78 | 1415.13 |
| XIV. | Other Comprehensive Income | | | | | | |
| | A. (i) Items that will not be reclassified to profit or loss | | | | | | |
| | (ii) Income tax relating to items that will not be reclassified to profit or loss | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | B. (i) Items that will be reclassified to profit or loss | | | | | | |
| | (ii) Income tax relating to items that will be reclassified to profit or loss | | | | | | |
| XV. | Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period) | 17436.41 | -7025.81 | -5180.62 | -2770.29 | 1874.78 | 1415.13 |
| XVI. | Paid-up equity share capital (Face Value Rs 10) | 37413.00 | 37413.00 | 37413.00 | 37413.00 | 37413.00 | 37413.00 |
| XVII. | Earnings per share (for continuing operation & discontinuing operation) (of Rs. 10/- each): | | | | | | |
| | (a) Basic | 4.66 | -1.88 | -1.38 | -0.74 | 0.50 | 0.38 |
| | (b) Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |

Notes:

1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 11.02.2023
 2. The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter and nine months ended 31st December, 2022
 3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
 4. Statement of Unaudited Financial Results of the company for the quarter and nine months ended 31st December, 2022, in the prescribed format under Schedule III of Companies Act, 2013
 5. The figures for the previous period have been regrouped wherever necessary.
- * The Company has decided to gradually write off its all Preliminary and Pre-operative expenses which are forming the part of Balance Sheet accordingly Company has written off Rs. 9,90,350/- during this quarter under review and it is forming part of Other Expenses.

Place Hadamtala (Rajkot)
Date: 11.02.2023

FOR, PARMAX PHARMA LIMITED

UMANG
ALKESH
GOSALIA

Digitally signed by
UMANG ALKESH
GOSALIA
Date: 2023.02.11
14:16:24 +05'30'

Dr. Umang Gosalia
Managing Director

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

Auditor's Limited Review Report On Unaudited Financial Results

To
The Board of Directors,
PARMAX PHARMA LIMITED

We have reviewed the accompanying statement of standalone unaudited financial results of **PARMAX PHARMA LTD** ("the Company") for the quarter and Nine months ended ended **31st December 2022** ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on **11th February 2023**. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (IND-AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there



Head Office:
209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Branch Office:
302-Vedant Complex,
7/B Kalpana Society,
C.G.Road, Navrangpura,
AHMEDABAD - 380 009
(GUJARAT)

Electronic Address:
(O) 0281-2468261

(M) 09427564149
(E) bassrmco.office@gmail.com
Or
mbshah_31@hotmail.com

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Rajkot

Date : 11.02.2023



For **B. A. SHAH S R MEHTA & Co.**
Chartered Accountants
FRN NO : 128796W

A handwritten signature in black ink that reads "Malay B. Shah".

MALAY B SHAH
Partner
M. No. 159526

UDIN : 23159526B64YPIG13037

Head Office:

209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Branch Office:

302-Vedant Complex,
7/B Kalpana Society,
C.G.Road, Navrangpura,
AHMEDABAD - 380 009
(GUJARAT)

Electronic Address:

(O) 0281-2468261
(M) 09427564149
(E) bassrmco.office@gmail.com
Or
mbshah_31@hotmail.com